The Pharmaceutical Research and Manufacturers of America has eliminated 22 companies from its membership, or about 42%, as part of an effort to refocus its constituency on research-based biopharmaceutical firms.
Under revised membership eligibility criteria approved by the board and announced May 9, companies joining PhRMA must have a three-year average global R&D-to-global sales ratio of 10% or greater and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?